SHAREHOLDER ALERT: Investigation of Sesen Bio, Inc. Announced by Holzer & Holzer, LLC

Atlanta, Georgia--(Newsfile Corp. - August 18, 2021) - Holzer & Holzer, LLC is investigating whether Sesen Bio, Inc. ("Sesen" or the "Company") (NASDAQ: SESN) complied with federal securities laws. On August 13, 2021, SESN received a Complete Response Letter from U.S. Food and Drug Administration ("FDA") and announced that the FDA had declined to approve the Biologics License Application for Vicineum. On this news, the price of the Company's stock plummeted.

If you purchased Sesen stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Joshua Karr, Esq. at jkarr@holzerlaw.com, call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com to discuss your legal rights.

Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.

CONTACT:
Corey D. Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/93594